Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Farzin Beygui: SOLOTAVI Tests Aspirin Discontinuation After TAVI
Nov 7, 2026, 14:00

Farzin Beygui: SOLOTAVI Tests Aspirin Discontinuation After TAVI

Farzin Beygui, Professor of Cardiology at University of Caen Normandy, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Heart Journal, adding:

“Proud to share the publication of the SOLOTAVI randomized trial design.

The study is assessing aspirin discontinuation at 90 days versus standard long term therapy after TAVI in patients with no ‘other’ indication for aspirin.

Congratulations and many thanks to the study investigators and co-authors of the 23 french centers, for their commitment and major envolvement that has already led to the recruitment of nearly half of the expected 1400.

Looking forward to sharing the results.”

Title: Rationale for Early Discontinuation of Aspirin After Transcatheter Aortic Valve Implantation: Design of the SOLOTAVI Randomized Trial

Authors: Farzin Beygui, Christophe Caussin, Stéphanie Marlière, Guillaume Bonnet, Eric Durand, Thibaud Lhermusier, Jean-Francois Morelle, Stéphane Delépine, Géraud Souteyrand, Said Ghostine, Eric Van Belle, Olivier Barthélémy, Mariama Akodad, Guillaume Cayla, Chekrallah Chamandi, Frank Chemouni, Jean-Jacques Parienti, Claire Bouleti, Hélène Eltchaninoff
Farzin Beygui: SOLOTAVI Tests Aspirin Discontinuation After TAVIStay updated with Hemostasis Today.